1. Innovotech Inc.
Annual General Meeting
20 April 2010
Edmonton, Alberta
www.innovotech.ca © Innovotech, 2009

2. Innovotech Inc.
AGENDA
 Welcome
 Formal Administrative Business
 Adjournment of AGM
 Business Update
 Q&A
www.innovotech.ca © Innovotech, 2009

3. Innovotech Inc.
Formal Administrative Business
www.innovotech.ca © Innovotech, 2009

4. Innovotech Inc.
Election of Directors:
 Dr Lorne Babiuk
 Mr Kerry Brown
 Mr Bruce D. Hirsche Q.C.
 Dr Wolfgang H. Muhs
 Mr John Pinsent
 Dr Gerard Tertzakian
 Dr James Timourian
www.innovotech.ca © Innovotech, 2009

5. Innovotech Business Update

6. 2009 – Moving to Market
Objectives & Performance in 2009
www.innovotech.ca © Innovotech, 2009

7. 2009 Financial Results
2009 2008
Revenue $1,453,924 $1,164,035
Gross Margin $813,629 $695,409
Overhead Costs $984,178 $909,588
R&D Expenditures $809,326 $708,007
EBIT ($1,136,783) ($983,261)
Accumulated Deficit ($3,618,938) ($2,491,735)
Shares Outstanding (wa) 23,985,784 21,907,352
Cash Reserves (Dec 31) $1,375,559 $2,120,859
www.innovotech.ca © Innovotech, 2009

8. bioFILM PA - Objectives
bioFILM PA goals for 2009:
 Revenue
 Expand through commercial partner
Path:
 Canada: Maintain current plan
 USA: “Research Use Only” through Partner
 Convert to dry panel
www.innovotech.ca © Innovotech, 2009

9. bioFILM PA -Stakeholders
Alberta Health Laboratory
Payer User
IOT
Patients Doctors
Recipient Decision-maker
www.innovotech.ca © Innovotech, 2009

10. bioFILM - Market potential
Market - bioFILM PA: Canada US World
 Cystic Fibrosis $2.4M $24M $50M
 Ventilator Associated Pneumonia $35M $70M
 Other (burns, wounds) tbd
Market – bioFILM SA: Canada US World
 Catheters
 Dialysis
 Other (CF, VAP)
Total >$150M
www.innovotech.ca © Innovotech, 2009

11. bioFILM PA – 2010 Objectives
 Revenue in Canada
 Published paper
 Health economic evaluation
 Enter other markets
 US through private diagnostic laboratory
 Israel
 SA development
 Low cost and quick development
 Augments PA disease use (CF and VAP)
www.innovotech.ca © Innovotech, 2009

12. Agress – Objectives
Agress goals for 2009:
 Regulatory approval for pulses
 Commercial agreement
Path:
 Maintain current Co interest
 Potential reg filing for Fire Blight
 Develop AUS R&D
 Launch in N America for pulses post-09
www.innovotech.ca © Innovotech, 2009

13. Agress – PMRA (Canada)
Current situation: New submission:
 Innovotech denied waiver  Determine EPA stance
claims  Use Syngenta regulatory
 Asked to re-submit with team
expedited review for  Evaluate current consultants
approved components  8 crops, 25 diseases, 2 use
 Fees partially refunded patterns
 4 crops, 13 diseases, 1 use
pattern
www.innovotech.ca © Innovotech, 2009

14. Agress – Syngenta partnership
 Agress to be used as “anti-bacterial” component of many
products
 Syngenta press release on partnership
 Post-trade show orders of 1.5kg of Agress
 Syngenta (US) interest in Pithium data in corn
www.innovotech.ca © Innovotech, 2009

15. Agress – 2010 Objectives
 Expand product claims
 Crop, Disease and Use pattern
 Incorporate Syngenta trials
 Remove regulatory hurdles
 Meet with agencies
 Draw on external scientific expertise
 Maintain flexibility with other companies
www.innovotech.ca © Innovotech, 2009

16. Silver Periodate opportunity
 Unique properties
 Patentable discovery
 Interest of medical device and agriculture companies
 Assembly of internal team
www.innovotech.ca © Innovotech, 2009

17. 2010 – Objectives
Our goals for 2010:
 bioFILM PA™  Revenue
 Enter US market
 Agress  Expand claims
 Remove regulatory hurdles
 R&D  Product candidate from Silver periodate
 Develop bioFILM SA
 Photo-dynamic approval as sanitizer
 Contract Research  Revenue growth
www.innovotech.ca © Innovotech, 2009

18. Contact Information
Ken Boutilier, President
Innovotech Inc.
ken.boutilier@innovotech.ca
Ph: 780-448-0585 ext 221
Fax: 780-424-0941
www.innovotech.ca © Innovotech, 2009

19. www.innovotech.ca © Innovotech, 2009

20. 2008 Summary - Agress™
Factors:
Seed & Foliar  Treatment is based on
All crops disease pressure
World  Crop guarantees by
$20B+ Seed Treatment, sellers increases
All crops treatments
North America  A suitable antibacterial
$120M is lacking
 Formulations are as
Seed Treatment, important as “actives”
Pulse crops  Agress will be in a
North America combination with other
$3-5M agents
www.innovotech.ca © Innovotech, 2009

21. Agress – Market Potential
Markets
100% Canola
Vegetables/ Fruit Trees/
Horticulture Bushes
Treatment Intensity (%)
80% Corn
Pulses
60%
Soybeans
40%
Cereals Agress is price
20% competitive in all
markets!
0%
-$500 $500 $1,500 $2,500 $3,500 $4,500
Value/Acre ($/ac)
www.innovotech.ca © Innovotech, 2009